UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

05 UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Read More Share:

Oct

27 Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

Read More Share:

Oct

16 Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Read More Share:

Sep

29 New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Read More Share:

Aug

30 UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Read More Share:

Apr

28 UCB Announces PDUFA Date for Bimekizumab

Read More Share:

Apr

23 "The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Read More Share:

Apr

23 UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Read More Share:

Feb

25 UCB - Sustaining Growth, Now and Into the Future

Read More Share:

Dec

03 UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

15 scientific presentations highlight data on BRIVACT^® (brivaracetam) CV, NAYZILAM^® (midazolam) nasal spray CIV, VIMPAT^® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel

Read More Share:

Categories

Archives

Nov

05

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Oct

27

Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Dec

03

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Nov

05

UCB Showcases Key Rheumatology Data at ACR Convergence 2021

Oct

27

Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy

Oct

16

Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

Sep

29

New Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congress

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Apr

28

UCB Announces PDUFA Date for Bimekizumab

Apr

23

"The New England Journal of Medicine" Publishes Results from Two Bimekizumab Phase 3 Studies in Moderate to Severe Plaque Psoriasis

Apr

23

UCB to Present 12 Abstracts on Bimekizumab at AAD VMX 2021

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Dec

03

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact